Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension

Patrick Crosswhite, Zhongjie Sun

Research output: Contribution to journalReview article

101 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by a persistent elevation of pulmonary artery pressure accompanied by right ventricular hypertrophy (RVH). The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown cause and pathogenesis of the disease. Both vasoconstriction and structural remodeling (enhanced proliferation of vascular smooth muscle cell) of the pulmonary arteries contribute to the progressive course of PAH, irrespective of different underlying causes. The exact molecular mechanism of PAH, however, is not fully understood. The purpose of this review is to provide recent advances in the mechanistic investigation of PAH. Specifically, this review focuses on nitric oxide, oxidative stress and inflammation and how these factors contribute to the development and progression of PAH. This review also discusses recent and potential therapeutic advancements for the treatment of PAH.

Original languageEnglish (US)
Pages (from-to)201-212
Number of pages12
JournalJournal of Hypertension
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Pulmonary Hypertension
Nitric Oxide
Oxidative Stress
Inflammation
Pulmonary Artery
Right Ventricular Hypertrophy
Vasoconstriction
Vascular Smooth Muscle
Smooth Muscle Myocytes
Chronic Disease
Pressure

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. / Crosswhite, Patrick; Sun, Zhongjie.

In: Journal of Hypertension, Vol. 28, No. 2, 01.02.2010, p. 201-212.

Research output: Contribution to journalReview article

@article{c5a562fbf4534cc7886105306eb1de1d,
title = "Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by a persistent elevation of pulmonary artery pressure accompanied by right ventricular hypertrophy (RVH). The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown cause and pathogenesis of the disease. Both vasoconstriction and structural remodeling (enhanced proliferation of vascular smooth muscle cell) of the pulmonary arteries contribute to the progressive course of PAH, irrespective of different underlying causes. The exact molecular mechanism of PAH, however, is not fully understood. The purpose of this review is to provide recent advances in the mechanistic investigation of PAH. Specifically, this review focuses on nitric oxide, oxidative stress and inflammation and how these factors contribute to the development and progression of PAH. This review also discusses recent and potential therapeutic advancements for the treatment of PAH.",
author = "Patrick Crosswhite and Zhongjie Sun",
year = "2010",
month = "2",
day = "1",
doi = "10.1097/HJH.0b013e328332bcdb",
language = "English (US)",
volume = "28",
pages = "201--212",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension

AU - Crosswhite, Patrick

AU - Sun, Zhongjie

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by a persistent elevation of pulmonary artery pressure accompanied by right ventricular hypertrophy (RVH). The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown cause and pathogenesis of the disease. Both vasoconstriction and structural remodeling (enhanced proliferation of vascular smooth muscle cell) of the pulmonary arteries contribute to the progressive course of PAH, irrespective of different underlying causes. The exact molecular mechanism of PAH, however, is not fully understood. The purpose of this review is to provide recent advances in the mechanistic investigation of PAH. Specifically, this review focuses on nitric oxide, oxidative stress and inflammation and how these factors contribute to the development and progression of PAH. This review also discusses recent and potential therapeutic advancements for the treatment of PAH.

AB - Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by a persistent elevation of pulmonary artery pressure accompanied by right ventricular hypertrophy (RVH). The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown cause and pathogenesis of the disease. Both vasoconstriction and structural remodeling (enhanced proliferation of vascular smooth muscle cell) of the pulmonary arteries contribute to the progressive course of PAH, irrespective of different underlying causes. The exact molecular mechanism of PAH, however, is not fully understood. The purpose of this review is to provide recent advances in the mechanistic investigation of PAH. Specifically, this review focuses on nitric oxide, oxidative stress and inflammation and how these factors contribute to the development and progression of PAH. This review also discusses recent and potential therapeutic advancements for the treatment of PAH.

UR - http://www.scopus.com/inward/record.url?scp=75149192272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149192272&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328332bcdb

DO - 10.1097/HJH.0b013e328332bcdb

M3 - Review article

VL - 28

SP - 201

EP - 212

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 2

ER -